nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxylamine—Disopyramide—SLC22A1—hematologic cancer	0.0011	0.193	CrCbGaD
Doxylamine—Toremifene—ESR1—hematologic cancer	0.000908	0.159	CrCbGaD
Doxylamine—Chlorphenamine—SLC22A1—hematologic cancer	0.000802	0.141	CrCbGaD
Doxylamine—Diphenhydramine—SLC22A1—hematologic cancer	0.000544	0.0954	CrCbGaD
Doxylamine—Imipramine—SLC22A1—hematologic cancer	0.000411	0.072	CrCbGaD
Doxylamine—Toremifene—ABCB1—hematologic cancer	0.000386	0.0676	CrCbGaD
Doxylamine—Tamoxifen—ABCG2—hematologic cancer	0.00037	0.0649	CrCbGaD
Doxylamine—Tamoxifen—ESR1—hematologic cancer	0.000363	0.0636	CrCbGaD
Doxylamine—Angioedema—Prednisone—hematologic cancer	0.000202	0.000216	CcSEcCtD
Doxylamine—Diarrhoea—Gemcitabine—hematologic cancer	0.000202	0.000215	CcSEcCtD
Doxylamine—Nausea—Thalidomide—hematologic cancer	0.000202	0.000215	CcSEcCtD
Doxylamine—Rash—Ifosfamide—hematologic cancer	0.000201	0.000215	CcSEcCtD
Doxylamine—Dermatitis—Ifosfamide—hematologic cancer	0.000201	0.000214	CcSEcCtD
Doxylamine—Erythema multiforme—Methotrexate—hematologic cancer	0.000201	0.000214	CcSEcCtD
Doxylamine—Hyperhidrosis—Dexamethasone—hematologic cancer	0.000201	0.000214	CcSEcCtD
Doxylamine—Hyperhidrosis—Betamethasone—hematologic cancer	0.000201	0.000214	CcSEcCtD
Doxylamine—Dizziness—Irinotecan—hematologic cancer	0.000201	0.000214	CcSEcCtD
Doxylamine—Urticaria—Etoposide—hematologic cancer	0.0002	0.000214	CcSEcCtD
Doxylamine—Malaise—Prednisone—hematologic cancer	0.0002	0.000213	CcSEcCtD
Doxylamine—Vertigo—Prednisone—hematologic cancer	0.000199	0.000212	CcSEcCtD
Doxylamine—Hepatitis—Epirubicin—hematologic cancer	0.000199	0.000212	CcSEcCtD
Doxylamine—Eye disorder—Methotrexate—hematologic cancer	0.000199	0.000212	CcSEcCtD
Doxylamine—Vomiting—Vincristine—hematologic cancer	0.000198	0.000211	CcSEcCtD
Doxylamine—Anorexia—Dexamethasone—hematologic cancer	0.000198	0.000211	CcSEcCtD
Doxylamine—Anorexia—Betamethasone—hematologic cancer	0.000198	0.000211	CcSEcCtD
Doxylamine—Urticaria—Prednisolone—hematologic cancer	0.000198	0.000211	CcSEcCtD
Doxylamine—Asthenia—Cisplatin—hematologic cancer	0.000198	0.000211	CcSEcCtD
Doxylamine—Cardiac disorder—Methotrexate—hematologic cancer	0.000197	0.00021	CcSEcCtD
Doxylamine—Fatigue—Triamcinolone—hematologic cancer	0.000197	0.00021	CcSEcCtD
Doxylamine—Sweating—Doxorubicin—hematologic cancer	0.000197	0.00021	CcSEcCtD
Doxylamine—Urinary tract disorder—Epirubicin—hematologic cancer	0.000197	0.00021	CcSEcCtD
Doxylamine—Rash—Vincristine—hematologic cancer	0.000196	0.000209	CcSEcCtD
Doxylamine—Dermatitis—Vincristine—hematologic cancer	0.000196	0.000209	CcSEcCtD
Doxylamine—Urethral disorder—Epirubicin—hematologic cancer	0.000195	0.000208	CcSEcCtD
Doxylamine—Hypotension—Betamethasone—hematologic cancer	0.000194	0.000207	CcSEcCtD
Doxylamine—Hypotension—Dexamethasone—hematologic cancer	0.000194	0.000207	CcSEcCtD
Doxylamine—Nausea—Carmustine—hematologic cancer	0.000194	0.000207	CcSEcCtD
Doxylamine—Vomiting—Irinotecan—hematologic cancer	0.000193	0.000206	CcSEcCtD
Doxylamine—Vomiting—Mitoxantrone—hematologic cancer	0.000193	0.000206	CcSEcCtD
Doxylamine—Immune system disorder—Methotrexate—hematologic cancer	0.000192	0.000205	CcSEcCtD
Doxylamine—Nausea—Alitretinoin—hematologic cancer	0.000192	0.000205	CcSEcCtD
Doxylamine—Convulsion—Prednisone—hematologic cancer	0.000192	0.000205	CcSEcCtD
Doxylamine—Mediastinal disorder—Methotrexate—hematologic cancer	0.000192	0.000204	CcSEcCtD
Doxylamine—Agranulocytosis—Doxorubicin—hematologic cancer	0.000191	0.000204	CcSEcCtD
Doxylamine—Rash—Mitoxantrone—hematologic cancer	0.000191	0.000204	CcSEcCtD
Doxylamine—Rash—Irinotecan—hematologic cancer	0.000191	0.000204	CcSEcCtD
Doxylamine—Dermatitis—Irinotecan—hematologic cancer	0.000191	0.000204	CcSEcCtD
Doxylamine—Dermatitis—Mitoxantrone—hematologic cancer	0.000191	0.000204	CcSEcCtD
Doxylamine—Nausea—Ifosfamide—hematologic cancer	0.00019	0.000202	CcSEcCtD
Doxylamine—Feeling abnormal—Triamcinolone—hematologic cancer	0.000189	0.000201	CcSEcCtD
Doxylamine—Diarrhoea—Cisplatin—hematologic cancer	0.000188	0.000201	CcSEcCtD
Doxylamine—Erythema multiforme—Epirubicin—hematologic cancer	0.000188	0.000201	CcSEcCtD
Doxylamine—Anxiety—Prednisone—hematologic cancer	0.000188	0.0002	CcSEcCtD
Doxylamine—Vomiting—Gemcitabine—hematologic cancer	0.000188	0.0002	CcSEcCtD
Doxylamine—Insomnia—Dexamethasone—hematologic cancer	0.000188	0.0002	CcSEcCtD
Doxylamine—Insomnia—Betamethasone—hematologic cancer	0.000188	0.0002	CcSEcCtD
Doxylamine—Bradycardia—Doxorubicin—hematologic cancer	0.000187	0.0002	CcSEcCtD
Doxylamine—Discomfort—Prednisone—hematologic cancer	0.000186	0.000199	CcSEcCtD
Doxylamine—Rash—Gemcitabine—hematologic cancer	0.000186	0.000199	CcSEcCtD
Doxylamine—Dermatitis—Gemcitabine—hematologic cancer	0.000186	0.000198	CcSEcCtD
Doxylamine—Eye disorder—Epirubicin—hematologic cancer	0.000186	0.000198	CcSEcCtD
Doxylamine—Hypersensitivity—Etoposide—hematologic cancer	0.000186	0.000198	CcSEcCtD
Doxylamine—Erythema—Methotrexate—hematologic cancer	0.000185	0.000197	CcSEcCtD
Doxylamine—Nausea—Vincristine—hematologic cancer	0.000185	0.000197	CcSEcCtD
Doxylamine—Flushing—Epirubicin—hematologic cancer	0.000185	0.000197	CcSEcCtD
Doxylamine—Cardiac disorder—Epirubicin—hematologic cancer	0.000185	0.000197	CcSEcCtD
Doxylamine—Hepatitis—Doxorubicin—hematologic cancer	0.000184	0.000196	CcSEcCtD
Doxylamine—Hypersensitivity—Prednisolone—hematologic cancer	0.000183	0.000195	CcSEcCtD
Doxylamine—Urinary tract disorder—Doxorubicin—hematologic cancer	0.000182	0.000194	CcSEcCtD
Doxylamine—Urticaria—Triamcinolone—hematologic cancer	0.000182	0.000194	CcSEcCtD
Doxylamine—Asthenia—Etoposide—hematologic cancer	0.000181	0.000193	CcSEcCtD
Doxylamine—Anaphylactic shock—Prednisone—hematologic cancer	0.000181	0.000193	CcSEcCtD
Doxylamine—Urethral disorder—Doxorubicin—hematologic cancer	0.000181	0.000192	CcSEcCtD
Doxylamine—Decreased appetite—Betamethasone—hematologic cancer	0.00018	0.000192	CcSEcCtD
Doxylamine—Decreased appetite—Dexamethasone—hematologic cancer	0.00018	0.000192	CcSEcCtD
Doxylamine—Nausea—Irinotecan—hematologic cancer	0.00018	0.000192	CcSEcCtD
Doxylamine—Nausea—Mitoxantrone—hematologic cancer	0.00018	0.000192	CcSEcCtD
Doxylamine—Immune system disorder—Epirubicin—hematologic cancer	0.00018	0.000192	CcSEcCtD
Doxylamine—Mediastinal disorder—Epirubicin—hematologic cancer	0.000179	0.000191	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	0.000179	0.000191	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Betamethasone—hematologic cancer	0.000179	0.000191	CcSEcCtD
Doxylamine—Fatigue—Dexamethasone—hematologic cancer	0.000179	0.000191	CcSEcCtD
Doxylamine—Fatigue—Betamethasone—hematologic cancer	0.000179	0.000191	CcSEcCtD
Doxylamine—Pruritus—Etoposide—hematologic cancer	0.000178	0.00019	CcSEcCtD
Doxylamine—Nervous system disorder—Prednisone—hematologic cancer	0.000177	0.000189	CcSEcCtD
Doxylamine—Tachycardia—Prednisone—hematologic cancer	0.000176	0.000188	CcSEcCtD
Doxylamine—Nausea—Gemcitabine—hematologic cancer	0.000175	0.000187	CcSEcCtD
Doxylamine—Vomiting—Cisplatin—hematologic cancer	0.000175	0.000187	CcSEcCtD
Doxylamine—Hyperhidrosis—Prednisone—hematologic cancer	0.000175	0.000186	CcSEcCtD
Doxylamine—Erythema multiforme—Doxorubicin—hematologic cancer	0.000174	0.000186	CcSEcCtD
Doxylamine—Rash—Cisplatin—hematologic cancer	0.000174	0.000185	CcSEcCtD
Doxylamine—Dermatitis—Cisplatin—hematologic cancer	0.000173	0.000185	CcSEcCtD
Doxylamine—Erythema—Epirubicin—hematologic cancer	0.000173	0.000185	CcSEcCtD
Doxylamine—Diarrhoea—Etoposide—hematologic cancer	0.000173	0.000184	CcSEcCtD
Doxylamine—Anorexia—Prednisone—hematologic cancer	0.000172	0.000184	CcSEcCtD
Doxylamine—Eye disorder—Doxorubicin—hematologic cancer	0.000172	0.000183	CcSEcCtD
Doxylamine—Ill-defined disorder—Methotrexate—hematologic cancer	0.000172	0.000183	CcSEcCtD
Doxylamine—Feeling abnormal—Betamethasone—hematologic cancer	0.000171	0.000182	CcSEcCtD
Doxylamine—Feeling abnormal—Dexamethasone—hematologic cancer	0.000171	0.000182	CcSEcCtD
Doxylamine—Cardiac disorder—Doxorubicin—hematologic cancer	0.000171	0.000182	CcSEcCtD
Doxylamine—Flushing—Doxorubicin—hematologic cancer	0.000171	0.000182	CcSEcCtD
Doxylamine—Hypersensitivity—Triamcinolone—hematologic cancer	0.000169	0.00018	CcSEcCtD
Doxylamine—Malaise—Methotrexate—hematologic cancer	0.000167	0.000178	CcSEcCtD
Doxylamine—Dizziness—Etoposide—hematologic cancer	0.000167	0.000178	CcSEcCtD
Doxylamine—Muscle spasms—Epirubicin—hematologic cancer	0.000167	0.000178	CcSEcCtD
Doxylamine—Immune system disorder—Doxorubicin—hematologic cancer	0.000166	0.000177	CcSEcCtD
Doxylamine—Vertigo—Methotrexate—hematologic cancer	0.000166	0.000177	CcSEcCtD
Doxylamine—Mediastinal disorder—Doxorubicin—hematologic cancer	0.000166	0.000177	CcSEcCtD
Doxylamine—Leukopenia—Methotrexate—hematologic cancer	0.000166	0.000177	CcSEcCtD
Doxylamine—Urticaria—Betamethasone—hematologic cancer	0.000165	0.000176	CcSEcCtD
Doxylamine—Urticaria—Dexamethasone—hematologic cancer	0.000165	0.000176	CcSEcCtD
Doxylamine—Dizziness—Prednisolone—hematologic cancer	0.000165	0.000175	CcSEcCtD
Doxylamine—Asthenia—Triamcinolone—hematologic cancer	0.000164	0.000175	CcSEcCtD
Doxylamine—Nausea—Cisplatin—hematologic cancer	0.000164	0.000174	CcSEcCtD
Doxylamine—Insomnia—Prednisone—hematologic cancer	0.000164	0.000174	CcSEcCtD
Doxylamine—Pruritus—Triamcinolone—hematologic cancer	0.000162	0.000173	CcSEcCtD
Doxylamine—Ill-defined disorder—Epirubicin—hematologic cancer	0.000161	0.000171	CcSEcCtD
Doxylamine—Convulsion—Methotrexate—hematologic cancer	0.00016	0.000171	CcSEcCtD
Doxylamine—Vomiting—Etoposide—hematologic cancer	0.00016	0.000171	CcSEcCtD
Doxylamine—Erythema—Doxorubicin—hematologic cancer	0.00016	0.000171	CcSEcCtD
Doxylamine—Agitation—Epirubicin—hematologic cancer	0.000159	0.00017	CcSEcCtD
Doxylamine—Rash—Etoposide—hematologic cancer	0.000159	0.00017	CcSEcCtD
Doxylamine—Dermatitis—Etoposide—hematologic cancer	0.000159	0.000169	CcSEcCtD
Doxylamine—Decreased appetite—Prednisone—hematologic cancer	0.000157	0.000168	CcSEcCtD
Doxylamine—Rash—Prednisolone—hematologic cancer	0.000157	0.000167	CcSEcCtD
Doxylamine—Dermatitis—Prednisolone—hematologic cancer	0.000157	0.000167	CcSEcCtD
Doxylamine—Malaise—Epirubicin—hematologic cancer	0.000156	0.000167	CcSEcCtD
Doxylamine—Fatigue—Prednisone—hematologic cancer	0.000156	0.000166	CcSEcCtD
Doxylamine—Discomfort—Methotrexate—hematologic cancer	0.000156	0.000166	CcSEcCtD
Doxylamine—Vertigo—Epirubicin—hematologic cancer	0.000156	0.000166	CcSEcCtD
Doxylamine—Leukopenia—Epirubicin—hematologic cancer	0.000155	0.000165	CcSEcCtD
Doxylamine—Constipation—Prednisone—hematologic cancer	0.000155	0.000165	CcSEcCtD
Doxylamine—Muscle spasms—Doxorubicin—hematologic cancer	0.000154	0.000164	CcSEcCtD
Doxylamine—Tamoxifen—ABCB1—hematologic cancer	0.000154	0.027	CrCbGaD
Doxylamine—Doxepin—ABCB1—hematologic cancer	0.000154	0.0269	CrCbGaD
Doxylamine—Palpitations—Epirubicin—hematologic cancer	0.000153	0.000163	CcSEcCtD
Doxylamine—Methadone—ABCB1—hematologic cancer	0.000153	0.0268	CrCbGaD
Doxylamine—Confusional state—Methotrexate—hematologic cancer	0.000152	0.000162	CcSEcCtD
Doxylamine—Dizziness—Triamcinolone—hematologic cancer	0.000151	0.000161	CcSEcCtD
Doxylamine—Anaphylactic shock—Methotrexate—hematologic cancer	0.000151	0.000161	CcSEcCtD
Doxylamine—Convulsion—Epirubicin—hematologic cancer	0.00015	0.00016	CcSEcCtD
Doxylamine—Nausea—Etoposide—hematologic cancer	0.00015	0.00016	CcSEcCtD
Doxylamine—Feeling abnormal—Prednisone—hematologic cancer	0.000149	0.000159	CcSEcCtD
Doxylamine—Asthenia—Betamethasone—hematologic cancer	0.000149	0.000159	CcSEcCtD
Doxylamine—Asthenia—Dexamethasone—hematologic cancer	0.000149	0.000159	CcSEcCtD
Doxylamine—Ill-defined disorder—Doxorubicin—hematologic cancer	0.000149	0.000159	CcSEcCtD
Doxylamine—Nervous system disorder—Methotrexate—hematologic cancer	0.000148	0.000158	CcSEcCtD
Doxylamine—Thrombocytopenia—Methotrexate—hematologic cancer	0.000148	0.000158	CcSEcCtD
Doxylamine—Nausea—Prednisolone—hematologic cancer	0.000148	0.000158	CcSEcCtD
Doxylamine—Agitation—Doxorubicin—hematologic cancer	0.000147	0.000157	CcSEcCtD
Doxylamine—Anxiety—Epirubicin—hematologic cancer	0.000147	0.000157	CcSEcCtD
Doxylamine—Pruritus—Dexamethasone—hematologic cancer	0.000147	0.000157	CcSEcCtD
Doxylamine—Pruritus—Betamethasone—hematologic cancer	0.000147	0.000157	CcSEcCtD
Doxylamine—Hyperhidrosis—Methotrexate—hematologic cancer	0.000146	0.000156	CcSEcCtD
Doxylamine—Discomfort—Epirubicin—hematologic cancer	0.000146	0.000155	CcSEcCtD
Doxylamine—Vomiting—Triamcinolone—hematologic cancer	0.000145	0.000155	CcSEcCtD
Doxylamine—Malaise—Doxorubicin—hematologic cancer	0.000145	0.000154	CcSEcCtD
Doxylamine—Rash—Triamcinolone—hematologic cancer	0.000144	0.000154	CcSEcCtD
Doxylamine—Dry mouth—Epirubicin—hematologic cancer	0.000144	0.000154	CcSEcCtD
Doxylamine—Dermatitis—Triamcinolone—hematologic cancer	0.000144	0.000154	CcSEcCtD
Doxylamine—Vertigo—Doxorubicin—hematologic cancer	0.000144	0.000154	CcSEcCtD
Doxylamine—Anorexia—Methotrexate—hematologic cancer	0.000144	0.000154	CcSEcCtD
Doxylamine—Urticaria—Prednisone—hematologic cancer	0.000144	0.000153	CcSEcCtD
Doxylamine—Leukopenia—Doxorubicin—hematologic cancer	0.000144	0.000153	CcSEcCtD
Doxylamine—Confusional state—Epirubicin—hematologic cancer	0.000143	0.000152	CcSEcCtD
Doxylamine—Diarrhoea—Dexamethasone—hematologic cancer	0.000142	0.000151	CcSEcCtD
Doxylamine—Diarrhoea—Betamethasone—hematologic cancer	0.000142	0.000151	CcSEcCtD
Doxylamine—Palpitations—Doxorubicin—hematologic cancer	0.000142	0.000151	CcSEcCtD
Doxylamine—Anaphylactic shock—Epirubicin—hematologic cancer	0.000141	0.000151	CcSEcCtD
Doxylamine—Hypotension—Methotrexate—hematologic cancer	0.000141	0.000151	CcSEcCtD
Doxylamine—Convulsion—Doxorubicin—hematologic cancer	0.000139	0.000148	CcSEcCtD
Doxylamine—Nervous system disorder—Epirubicin—hematologic cancer	0.000139	0.000148	CcSEcCtD
Doxylamine—Thrombocytopenia—Epirubicin—hematologic cancer	0.000138	0.000148	CcSEcCtD
Doxylamine—Tachycardia—Epirubicin—hematologic cancer	0.000138	0.000147	CcSEcCtD
Doxylamine—Dizziness—Betamethasone—hematologic cancer	0.000137	0.000146	CcSEcCtD
Doxylamine—Dizziness—Dexamethasone—hematologic cancer	0.000137	0.000146	CcSEcCtD
Doxylamine—Hyperhidrosis—Epirubicin—hematologic cancer	0.000137	0.000146	CcSEcCtD
Doxylamine—Insomnia—Methotrexate—hematologic cancer	0.000137	0.000146	CcSEcCtD
Doxylamine—Anxiety—Doxorubicin—hematologic cancer	0.000136	0.000145	CcSEcCtD
Doxylamine—Nausea—Triamcinolone—hematologic cancer	0.000136	0.000145	CcSEcCtD
Doxylamine—Discomfort—Doxorubicin—hematologic cancer	0.000135	0.000144	CcSEcCtD
Doxylamine—Anorexia—Epirubicin—hematologic cancer	0.000135	0.000144	CcSEcCtD
Doxylamine—Dyspnoea—Methotrexate—hematologic cancer	0.000135	0.000144	CcSEcCtD
Doxylamine—Somnolence—Methotrexate—hematologic cancer	0.000134	0.000143	CcSEcCtD
Doxylamine—Dry mouth—Doxorubicin—hematologic cancer	0.000133	0.000142	CcSEcCtD
Doxylamine—Hypersensitivity—Prednisone—hematologic cancer	0.000133	0.000142	CcSEcCtD
Doxylamine—Hypotension—Epirubicin—hematologic cancer	0.000132	0.000141	CcSEcCtD
Doxylamine—Vomiting—Betamethasone—hematologic cancer	0.000132	0.000141	CcSEcCtD
Doxylamine—Vomiting—Dexamethasone—hematologic cancer	0.000132	0.000141	CcSEcCtD
Doxylamine—Confusional state—Doxorubicin—hematologic cancer	0.000132	0.000141	CcSEcCtD
Doxylamine—Decreased appetite—Methotrexate—hematologic cancer	0.000131	0.00014	CcSEcCtD
Doxylamine—Rash—Dexamethasone—hematologic cancer	0.000131	0.00014	CcSEcCtD
Doxylamine—Rash—Betamethasone—hematologic cancer	0.000131	0.00014	CcSEcCtD
Doxylamine—Anaphylactic shock—Doxorubicin—hematologic cancer	0.000131	0.000139	CcSEcCtD
Doxylamine—Dermatitis—Dexamethasone—hematologic cancer	0.000131	0.000139	CcSEcCtD
Doxylamine—Dermatitis—Betamethasone—hematologic cancer	0.000131	0.000139	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Methotrexate—hematologic cancer	0.00013	0.000139	CcSEcCtD
Doxylamine—Fatigue—Methotrexate—hematologic cancer	0.00013	0.000139	CcSEcCtD
Doxylamine—Asthenia—Prednisone—hematologic cancer	0.00013	0.000138	CcSEcCtD
Doxylamine—Nervous system disorder—Doxorubicin—hematologic cancer	0.000128	0.000137	CcSEcCtD
Doxylamine—Thrombocytopenia—Doxorubicin—hematologic cancer	0.000128	0.000137	CcSEcCtD
Doxylamine—Pruritus—Prednisone—hematologic cancer	0.000128	0.000136	CcSEcCtD
Doxylamine—Insomnia—Epirubicin—hematologic cancer	0.000128	0.000136	CcSEcCtD
Doxylamine—Tachycardia—Doxorubicin—hematologic cancer	0.000128	0.000136	CcSEcCtD
Doxylamine—Hyperhidrosis—Doxorubicin—hematologic cancer	0.000126	0.000135	CcSEcCtD
Doxylamine—Dyspnoea—Epirubicin—hematologic cancer	0.000126	0.000134	CcSEcCtD
Doxylamine—Somnolence—Epirubicin—hematologic cancer	0.000126	0.000134	CcSEcCtD
Doxylamine—Anorexia—Doxorubicin—hematologic cancer	0.000125	0.000133	CcSEcCtD
Doxylamine—Feeling abnormal—Methotrexate—hematologic cancer	0.000125	0.000133	CcSEcCtD
Doxylamine—Amitriptyline—ALB—hematologic cancer	0.000125	0.0218	CrCbGaD
Doxylamine—Diarrhoea—Prednisone—hematologic cancer	0.000124	0.000132	CcSEcCtD
Doxylamine—Nausea—Dexamethasone—hematologic cancer	0.000123	0.000131	CcSEcCtD
Doxylamine—Nausea—Betamethasone—hematologic cancer	0.000123	0.000131	CcSEcCtD
Doxylamine—Decreased appetite—Epirubicin—hematologic cancer	0.000123	0.000131	CcSEcCtD
Doxylamine—Hypotension—Doxorubicin—hematologic cancer	0.000122	0.00013	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Epirubicin—hematologic cancer	0.000122	0.00013	CcSEcCtD
Doxylamine—Fatigue—Epirubicin—hematologic cancer	0.000122	0.00013	CcSEcCtD
Doxylamine—Constipation—Epirubicin—hematologic cancer	0.000121	0.000129	CcSEcCtD
Doxylamine—Urticaria—Methotrexate—hematologic cancer	0.00012	0.000128	CcSEcCtD
Doxylamine—Dizziness—Prednisone—hematologic cancer	0.00012	0.000127	CcSEcCtD
Doxylamine—Imipramine—ABCB1—hematologic cancer	0.00012	0.0209	CrCbGaD
Doxylamine—Amitriptyline—ABCB1—hematologic cancer	0.000119	0.0208	CrCbGaD
Doxylamine—Insomnia—Doxorubicin—hematologic cancer	0.000118	0.000126	CcSEcCtD
Doxylamine—Dyspnoea—Doxorubicin—hematologic cancer	0.000117	0.000124	CcSEcCtD
Doxylamine—Feeling abnormal—Epirubicin—hematologic cancer	0.000117	0.000124	CcSEcCtD
Doxylamine—Somnolence—Doxorubicin—hematologic cancer	0.000116	0.000124	CcSEcCtD
Doxylamine—Vomiting—Prednisone—hematologic cancer	0.000115	0.000123	CcSEcCtD
Doxylamine—Rash—Prednisone—hematologic cancer	0.000114	0.000122	CcSEcCtD
Doxylamine—Dermatitis—Prednisone—hematologic cancer	0.000114	0.000121	CcSEcCtD
Doxylamine—Decreased appetite—Doxorubicin—hematologic cancer	0.000114	0.000121	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	0.000113	0.00012	CcSEcCtD
Doxylamine—Fatigue—Doxorubicin—hematologic cancer	0.000113	0.00012	CcSEcCtD
Doxylamine—Urticaria—Epirubicin—hematologic cancer	0.000112	0.00012	CcSEcCtD
Doxylamine—Constipation—Doxorubicin—hematologic cancer	0.000112	0.000119	CcSEcCtD
Doxylamine—Hypersensitivity—Methotrexate—hematologic cancer	0.000111	0.000119	CcSEcCtD
Doxylamine—Asthenia—Methotrexate—hematologic cancer	0.000108	0.000116	CcSEcCtD
Doxylamine—Feeling abnormal—Doxorubicin—hematologic cancer	0.000108	0.000115	CcSEcCtD
Doxylamine—Nausea—Prednisone—hematologic cancer	0.000107	0.000114	CcSEcCtD
Doxylamine—Pruritus—Methotrexate—hematologic cancer	0.000107	0.000114	CcSEcCtD
Doxylamine—Hypersensitivity—Epirubicin—hematologic cancer	0.000104	0.000111	CcSEcCtD
Doxylamine—Urticaria—Doxorubicin—hematologic cancer	0.000104	0.000111	CcSEcCtD
Doxylamine—Diarrhoea—Methotrexate—hematologic cancer	0.000103	0.00011	CcSEcCtD
Doxylamine—Asthenia—Epirubicin—hematologic cancer	0.000101	0.000108	CcSEcCtD
Doxylamine—Pruritus—Epirubicin—hematologic cancer	0.0001	0.000107	CcSEcCtD
Doxylamine—Dizziness—Methotrexate—hematologic cancer	9.99e-05	0.000107	CcSEcCtD
Doxylamine—Diarrhoea—Epirubicin—hematologic cancer	9.68e-05	0.000103	CcSEcCtD
Doxylamine—Hypersensitivity—Doxorubicin—hematologic cancer	9.64e-05	0.000103	CcSEcCtD
Doxylamine—Vomiting—Methotrexate—hematologic cancer	9.61e-05	0.000102	CcSEcCtD
Doxylamine—Rash—Methotrexate—hematologic cancer	9.53e-05	0.000102	CcSEcCtD
Doxylamine—Dermatitis—Methotrexate—hematologic cancer	9.52e-05	0.000101	CcSEcCtD
Doxylamine—Asthenia—Doxorubicin—hematologic cancer	9.39e-05	0.0001	CcSEcCtD
Doxylamine—Dizziness—Epirubicin—hematologic cancer	9.35e-05	9.97e-05	CcSEcCtD
Doxylamine—Pruritus—Doxorubicin—hematologic cancer	9.26e-05	9.87e-05	CcSEcCtD
Doxylamine—Vomiting—Epirubicin—hematologic cancer	8.99e-05	9.58e-05	CcSEcCtD
Doxylamine—Nausea—Methotrexate—hematologic cancer	8.98e-05	9.57e-05	CcSEcCtD
Doxylamine—Diarrhoea—Doxorubicin—hematologic cancer	8.95e-05	9.54e-05	CcSEcCtD
Doxylamine—Rash—Epirubicin—hematologic cancer	8.92e-05	9.5e-05	CcSEcCtD
Doxylamine—Dermatitis—Epirubicin—hematologic cancer	8.91e-05	9.5e-05	CcSEcCtD
Doxylamine—Dizziness—Doxorubicin—hematologic cancer	8.65e-05	9.22e-05	CcSEcCtD
Doxylamine—Nausea—Epirubicin—hematologic cancer	8.4e-05	8.95e-05	CcSEcCtD
Doxylamine—Vomiting—Doxorubicin—hematologic cancer	8.32e-05	8.87e-05	CcSEcCtD
Doxylamine—Rash—Doxorubicin—hematologic cancer	8.25e-05	8.79e-05	CcSEcCtD
Doxylamine—Dermatitis—Doxorubicin—hematologic cancer	8.24e-05	8.79e-05	CcSEcCtD
Doxylamine—Nausea—Doxorubicin—hematologic cancer	7.77e-05	8.28e-05	CcSEcCtD
Doxylamine—CHRM1—GPCR downstream signaling—PRKCG—hematologic cancer	3.32e-05	0.000592	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—RAC2—hematologic cancer	3.31e-05	0.00059	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—DKK1—hematologic cancer	3.3e-05	0.000588	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—DKK1—hematologic cancer	3.29e-05	0.000586	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—STAT5B—hematologic cancer	3.27e-05	0.000583	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—STAT5B—hematologic cancer	3.26e-05	0.000581	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ADCY7—hematologic cancer	3.17e-05	0.000566	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ADCY7—hematologic cancer	3.16e-05	0.000564	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CSF2—hematologic cancer	3.13e-05	0.000558	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CSF2—hematologic cancer	3.12e-05	0.000557	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—IL2RA—hematologic cancer	3.11e-05	0.000554	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—IL2RA—hematologic cancer	3.1e-05	0.000553	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—XIAP—hematologic cancer	3.09e-05	0.000551	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—XIAP—hematologic cancer	3.08e-05	0.000549	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—JAK1—hematologic cancer	3.02e-05	0.000539	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PRKCG—hematologic cancer	3.02e-05	0.000539	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PRKCG—hematologic cancer	3.01e-05	0.000537	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—JAK1—hematologic cancer	3.01e-05	0.000537	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SH2B3—hematologic cancer	3.01e-05	0.000537	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SMARCA4—hematologic cancer	3.01e-05	0.000537	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SH2B3—hematologic cancer	3e-05	0.000535	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SMARCA4—hematologic cancer	3e-05	0.000535	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GZMB—hematologic cancer	2.99e-05	0.000533	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GZMB—hematologic cancer	2.98e-05	0.000532	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CTNNA1—hematologic cancer	2.92e-05	0.000521	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CTNNA1—hematologic cancer	2.91e-05	0.000519	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—EIF4EBP1—hematologic cancer	2.9e-05	0.000518	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HSPB1—hematologic cancer	2.9e-05	0.000518	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCL3—hematologic cancer	2.9e-05	0.000518	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HSPB1—hematologic cancer	2.89e-05	0.000516	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—EIF4EBP1—hematologic cancer	2.89e-05	0.000516	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCL3—hematologic cancer	2.89e-05	0.000516	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PTHLH—hematologic cancer	2.87e-05	0.000512	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SDC1—hematologic cancer	2.87e-05	0.000512	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PTHLH—hematologic cancer	2.86e-05	0.00051	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SDC1—hematologic cancer	2.86e-05	0.00051	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—IL2RA—hematologic cancer	2.82e-05	0.000503	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—IL2RA—hematologic cancer	2.81e-05	0.000502	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PTGER4—hematologic cancer	2.8e-05	0.000498	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PTGER4—hematologic cancer	2.79e-05	0.000497	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—LCK—hematologic cancer	2.78e-05	0.000496	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—LCK—hematologic cancer	2.77e-05	0.000494	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—H3F3A—hematologic cancer	2.73e-05	0.000486	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—H3F3A—hematologic cancer	2.72e-05	0.000484	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PRKCZ—hematologic cancer	2.65e-05	0.000472	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PRKCZ—hematologic cancer	2.64e-05	0.000471	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CG—hematologic cancer	2.59e-05	0.000462	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CG—hematologic cancer	2.58e-05	0.00046	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PARP1—hematologic cancer	2.56e-05	0.000456	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PARP1—hematologic cancer	2.55e-05	0.000455	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FBXW7—hematologic cancer	2.52e-05	0.000449	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FBXW7—hematologic cancer	2.51e-05	0.000447	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HDAC2—hematologic cancer	2.47e-05	0.00044	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CXCR4—hematologic cancer	2.47e-05	0.00044	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CXCR4—hematologic cancer	2.46e-05	0.000439	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HDAC2—hematologic cancer	2.46e-05	0.000439	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CBL—hematologic cancer	2.41e-05	0.000429	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CBL—hematologic cancer	2.4e-05	0.000428	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IL3—hematologic cancer	2.38e-05	0.000424	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IL3—hematologic cancer	2.37e-05	0.000423	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CG—hematologic cancer	2.35e-05	0.000419	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CG—hematologic cancer	2.34e-05	0.000418	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PTPN1—hematologic cancer	2.34e-05	0.000417	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PTPN1—hematologic cancer	2.33e-05	0.000416	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PTPN11—hematologic cancer	2.31e-05	0.000412	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PTPN11—hematologic cancer	2.3e-05	0.000411	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—RASGRP1—hematologic cancer	2.3e-05	0.000411	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HSP90AA1—hematologic cancer	2.3e-05	0.000409	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SYK—hematologic cancer	2.3e-05	0.000409	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—RASGRP1—hematologic cancer	2.3e-05	0.000409	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SYK—hematologic cancer	2.29e-05	0.000408	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HSP90AA1—hematologic cancer	2.29e-05	0.000408	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CD—hematologic cancer	2.28e-05	0.000406	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CD—hematologic cancer	2.27e-05	0.000405	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CREB1—hematologic cancer	2.24e-05	0.000399	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CREB1—hematologic cancer	2.23e-05	0.000398	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—STAT1—hematologic cancer	2.21e-05	0.000395	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—STAT1—hematologic cancer	2.21e-05	0.000393	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CCL2—hematologic cancer	2.19e-05	0.000391	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—IL6R—hematologic cancer	2.18e-05	0.000389	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CCL2—hematologic cancer	2.18e-05	0.000389	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—IL6R—hematologic cancer	2.18e-05	0.000388	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3R1—hematologic cancer	2.15e-05	0.000383	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3R1—hematologic cancer	2.14e-05	0.000382	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—JAK2—hematologic cancer	2.09e-05	0.000373	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—JAK2—hematologic cancer	2.08e-05	0.000371	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—MAP2K1—hematologic cancer	2.08e-05	0.000371	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—MAP2K1—hematologic cancer	2.07e-05	0.00037	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GRB2—hematologic cancer	2.07e-05	0.000369	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CD—hematologic cancer	2.07e-05	0.000369	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PDGFA—hematologic cancer	2.07e-05	0.000368	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GRB2—hematologic cancer	2.06e-05	0.000368	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CD—hematologic cancer	2.06e-05	0.000367	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PDGFA—hematologic cancer	2.06e-05	0.000367	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—KITLG—hematologic cancer	2.04e-05	0.000363	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—KITLG—hematologic cancer	2.03e-05	0.000362	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—STAT5A—hematologic cancer	1.99e-05	0.000355	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CB—hematologic cancer	1.98e-05	0.000354	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—STAT5A—hematologic cancer	1.98e-05	0.000354	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CB—hematologic cancer	1.98e-05	0.000353	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CDKN2B—hematologic cancer	1.97e-05	0.000352	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CDKN2B—hematologic cancer	1.97e-05	0.000351	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3R1—hematologic cancer	1.95e-05	0.000348	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3R1—hematologic cancer	1.95e-05	0.000347	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CD86—hematologic cancer	1.91e-05	0.00034	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CD86—hematologic cancer	1.9e-05	0.000339	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—JAK2—hematologic cancer	1.9e-05	0.000338	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—JAK2—hematologic cancer	1.89e-05	0.000337	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HES1—hematologic cancer	1.88e-05	0.000336	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HES1—hematologic cancer	1.88e-05	0.000334	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NCOR1—hematologic cancer	1.87e-05	0.000334	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NCOR1—hematologic cancer	1.87e-05	0.000333	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CSF2—hematologic cancer	1.85e-05	0.00033	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FGF1—hematologic cancer	1.85e-05	0.00033	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CSF2—hematologic cancer	1.84e-05	0.000329	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FGF1—hematologic cancer	1.84e-05	0.000329	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FOXO1—hematologic cancer	1.82e-05	0.000325	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—IL2—hematologic cancer	1.82e-05	0.000325	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PDGFRB—hematologic cancer	1.82e-05	0.000325	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FOXO1—hematologic cancer	1.82e-05	0.000324	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—IL2—hematologic cancer	1.82e-05	0.000324	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PDGFRB—hematologic cancer	1.81e-05	0.000323	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CB—hematologic cancer	1.8e-05	0.000321	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CB—hematologic cancer	1.8e-05	0.00032	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PDGFRA—hematologic cancer	1.79e-05	0.000319	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PDGFRA—hematologic cancer	1.79e-05	0.000318	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—JAK1—hematologic cancer	1.79e-05	0.000318	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PRKCG—hematologic cancer	1.79e-05	0.000318	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—JAK1—hematologic cancer	1.78e-05	0.000317	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PRKCG—hematologic cancer	1.78e-05	0.000317	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IL2RA—hematologic cancer	1.67e-05	0.000297	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IL2RA—hematologic cancer	1.66e-05	0.000296	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—IL2—hematologic cancer	1.66e-05	0.000295	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—IL2—hematologic cancer	1.65e-05	0.000294	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TERT—hematologic cancer	1.65e-05	0.000294	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TERT—hematologic cancer	1.64e-05	0.000293	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PDGFB—hematologic cancer	1.61e-05	0.000287	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PDGFB—hematologic cancer	1.6e-05	0.000286	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TSC2—hematologic cancer	1.57e-05	0.00028	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TSC2—hematologic cancer	1.57e-05	0.00028	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FGFR3—hematologic cancer	1.51e-05	0.00027	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FGFR3—hematologic cancer	1.51e-05	0.000269	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MAPK14—hematologic cancer	1.5e-05	0.000267	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MAPK14—hematologic cancer	1.49e-05	0.000266	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ESR1—hematologic cancer	1.47e-05	0.000262	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ESR1—hematologic cancer	1.47e-05	0.000261	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FN1—hematologic cancer	1.45e-05	0.000259	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FN1—hematologic cancer	1.45e-05	0.000258	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NFKBIA—hematologic cancer	1.43e-05	0.000256	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—BAD—hematologic cancer	1.43e-05	0.000256	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NFKBIA—hematologic cancer	1.43e-05	0.000255	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—BAD—hematologic cancer	1.43e-05	0.000255	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NOTCH1—hematologic cancer	1.42e-05	0.000253	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NOTCH1—hematologic cancer	1.42e-05	0.000253	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CD80—hematologic cancer	1.39e-05	0.000248	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CG—hematologic cancer	1.39e-05	0.000248	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—KIT—hematologic cancer	1.39e-05	0.000248	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—NRAS—hematologic cancer	1.39e-05	0.000248	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CD80—hematologic cancer	1.39e-05	0.000247	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—KIT—hematologic cancer	1.39e-05	0.000247	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CG—hematologic cancer	1.39e-05	0.000247	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	1.38e-05	0.000247	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PTPN11—hematologic cancer	1.37e-05	0.000243	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	1.36e-05	0.000243	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—MAPK3—hematologic cancer	1.33e-05	0.000237	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	1.33e-05	0.000236	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CREB1—hematologic cancer	1.32e-05	0.000236	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CREB1—hematologic cancer	1.32e-05	0.000235	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—BRAF—hematologic cancer	1.31e-05	0.000233	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—BRAF—hematologic cancer	1.3e-05	0.000232	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCL2—hematologic cancer	1.29e-05	0.000231	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IL6R—hematologic cancer	1.29e-05	0.00023	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCL2—hematologic cancer	1.29e-05	0.00023	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CREBBP—hematologic cancer	1.29e-05	0.00023	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IL6R—hematologic cancer	1.29e-05	0.000229	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	1.28e-05	0.000229	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MAP2K1—hematologic cancer	1.23e-05	0.000219	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	1.23e-05	0.000219	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CD—hematologic cancer	1.22e-05	0.000218	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	1.22e-05	0.000217	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.21e-05	0.000216	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.21e-05	0.000215	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—KRAS—hematologic cancer	1.2e-05	0.000213	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	1.19e-05	0.000213	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FGF2—hematologic cancer	1.17e-05	0.000209	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FGF2—hematologic cancer	1.17e-05	0.000208	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3R1—hematologic cancer	1.15e-05	0.000206	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	1.15e-05	0.000205	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—JAK2—hematologic cancer	1.12e-05	0.0002	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—JAK2—hematologic cancer	1.12e-05	0.000199	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CA—hematologic cancer	1.1e-05	0.000196	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	1.1e-05	0.000195	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MDM2—hematologic cancer	1.09e-05	0.000195	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MDM2—hematologic cancer	1.09e-05	0.000194	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MTOR—hematologic cancer	1.06e-05	0.00019	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CB—hematologic cancer	1.06e-05	0.00019	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	1.06e-05	0.000189	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MTOR—hematologic cancer	1.06e-05	0.000189	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—HRAS—hematologic cancer	1.02e-05	0.000181	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	1.01e-05	0.000181	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CDKN1B—hematologic cancer	9.99e-06	0.000178	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	9.96e-06	0.000178	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—AKT1—hematologic cancer	9.88e-06	0.000176	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	9.85e-06	0.000176	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CASP3—hematologic cancer	9.79e-06	0.000175	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IL2—hematologic cancer	9.78e-06	0.000174	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CASP3—hematologic cancer	9.76e-06	0.000174	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IL2—hematologic cancer	9.75e-06	0.000174	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—IL6—hematologic cancer	9.73e-06	0.000173	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—IL6—hematologic cancer	9.7e-06	0.000173	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCND1—hematologic cancer	9.53e-06	0.00017	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—JUN—hematologic cancer	9.51e-06	0.00017	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCND1—hematologic cancer	9.5e-06	0.000169	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—JUN—hematologic cancer	9.48e-06	0.000169	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CDKN1A—hematologic cancer	9.22e-06	0.000164	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PTEN—hematologic cancer	9.2e-06	0.000164	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	9.19e-06	0.000164	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PTEN—hematologic cancer	9.17e-06	0.000163	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MAPK8—hematologic cancer	9e-06	0.00016	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—AKT1—hematologic cancer	8.98e-06	0.00016	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	8.97e-06	0.00016	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	8.95e-06	0.00016	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—EP300—hematologic cancer	8.77e-06	0.000156	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—EP300—hematologic cancer	8.75e-06	0.000156	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SRC—hematologic cancer	8.53e-06	0.000152	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SRC—hematologic cancer	8.5e-06	0.000152	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—VEGFA—hematologic cancer	8.31e-06	0.000148	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	8.28e-06	0.000148	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—STAT3—hematologic cancer	8.23e-06	0.000147	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NRAS—hematologic cancer	8.21e-06	0.000146	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—STAT3—hematologic cancer	8.2e-06	0.000146	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NRAS—hematologic cancer	8.18e-06	0.000146	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MAPK3—hematologic cancer	7.86e-06	0.00014	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	7.84e-06	0.00014	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MYC—hematologic cancer	7.65e-06	0.000136	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TGFB1—hematologic cancer	7.63e-06	0.000136	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MYC—hematologic cancer	7.62e-06	0.000136	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	7.6e-06	0.000136	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—KRAS—hematologic cancer	7.06e-06	0.000126	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—KRAS—hematologic cancer	7.04e-06	0.000126	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	6.49e-06	0.000116	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	6.47e-06	0.000115	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TP53—hematologic cancer	6.28e-06	0.000112	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TP53—hematologic cancer	6.26e-06	0.000112	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HRAS—hematologic cancer	6e-06	0.000107	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HRAS—hematologic cancer	5.99e-06	0.000107	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IL6—hematologic cancer	5.75e-06	0.000102	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IL6—hematologic cancer	5.73e-06	0.000102	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—AKT1—hematologic cancer	5.3e-06	9.45e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—AKT1—hematologic cancer	5.28e-06	9.42e-05	CbGpPWpGaD
